In the New World, cutaneous leishmaniasis presents in forms with different clinical, histological and immune characteristics and differing grades of severity ( [@B10]). The most common clinical form is localised cutaneous leishmaniasis (LCL), in which lesions usually heal spontaneously and predominantly exhibit a T-helper (Th)1 immune response associated with a delayed hypersensitivity reaction. Some infected individuals develop diffuse cutaneous leishmaniasis (DCL), which is characterised by multiple non-healing lesions and a predominant Th2 immune response associated with the production of non-protective antibodies ([@B08], [@B10]). Chronic cutaneous leishmaniasis, also called intermediate cutaneous leishmaniasis (ICL), is a persistent form that presents with extensive cutaneous lesions containing plaques and ulcers and is characterised by an exacerbated cell-mediated immune response that forms a granuloma containing many activated T cells and produces a variety of cytokines (Cace-res-Dittmar et al. 1993, [@B11]).

The regulation of cellular migration from lymphoid to peripheral tissues plays an important role in the immune response and chemokines and chemokine receptors are critical to the molecular mechanisms driving in this process. The recruitment of naïve and memory T cells to peripheral tissue is mediated by a combination of adhesion molecules and chemokine receptors ([@B18]). It is also known that cytokines are directly involved in chemokine production and may precede the expression of chemokines ([@B21]). In fact, interleukin (IL)-12 is required for the induction of Th1-related chemokines such as XCL1 (also known as lymphotactin), CXCL10 \[induced protein-10 (IP-10)\] and CCL2 \[monocyte chemoattractant protein (MCP)1\] ( [@B37]) and interferon (IFN)-γ selectively induces CXCL10 and CXCL9 (monokine induced by IFN-γ) ([@B12]). Other chemokines, such as CXCL5 (RANTES) and CCL11 (eotaxin), have been associated with a Th2 response. Although chemokine receptors are not exclusively expressed on specific T cell subsets ([@B17]), CXCR3 appears to be expressed by most Th1 cells, whereas CCR3 is expressed primarily by Th2 cells ([@B07], [@B27]).

The role of chemokines in *Leishmania* infection has been exhaustively studied and these findings indicate that chemokines and chemokine receptors play a crucial role in determining the outcome of the disease ([@B30]).

During early *Leishmania* infection in mice, the inflammatory infiltrate is composed of polymorphonuclear cells (PMNs) and macrophages ([@B28], [@B22]). Humans PMNs containing *Leishmania* parasites produce CXCL8 (IL-8) and CCL4 \[macrophage inflammatory protein (MIP)1β\], which are essential for recruiting macrophages and PMNs to the site of infection (van Zandbergen et al. 2004). Adaptive immunity is triggered by dendritic cells (DCs) in the skin that internalise *Leishmania* parasite antigens and transporting them from the skin to the draining lymph node for antigen presentation to naïve T cells. This migratory ability depends on the expression of CCR7, the receptor for CCL21 that is expressed in lymphoid tissues ([@B13]).

Despite the numerous studies describing chemokine participation in the immune response to *Leishmania*, very little is known about the chemokine and chemokine receptor expression patterns in human cutaneous leishmaniasis. [@B24] found that CCL2 and CCL3 (MIP1α) appear to be responsible for macrophage activation in skin lesions. Similarly, LCL patients infected with *Leishmania mexicana* exhibited high CCL2, CXCL9 and CXCL10 expression levels that were associated with a concentrated dermal infiltrate comprising macrophages and large numbers of CD4-positive T cells. In contrast, higher levels of CCL3 and lower levels of CXCL10 expression were present in non-healing DCL lesions, which were characterised by a more diffuse infiltrate with fewer CD4-positive T cells ([@B23]). Recently, high expression of CXCR3 has been observed in the early stages of LCL lesion, whereas a higher expression level of CCL7 is typically observed in DCL lesions, suggesting that different types of cells are recruited to the site of infection for different clinical forms ([@B09]).

In this study, we evaluated the local production of chemokines related to Th1/Th2 responses, including CXCL10, CCL4, CCL8, CCL11 and CXCL8, as well as the expression of the receptors CCR3, CXCR3, CCR5 and CCR7 in the lesions of patients with different clinical forms of American cutaneous leishmaniasis (ACL) using immunohistochemistry. Patients exhibited different chemokine expression patterns related to the type of adaptive response that was observed. CXCR3-positive lymphocyte recruitment was increased in LCL and ICL patients, whereas DCL and ICL patients showed increased expression of CCL11 in epidermal DCs.

PATIENTS, MATERIALS AND METHODS
===============================

*Patients* - This study included patients with LCL (n = 20), ICL (n = 5) and DCL (n = 10) who were treated at the Institute of Biomedicine, Caracas, Venezuela. Before starting the study, the project was approved by the Ethical Committee of the Institute of Biomedicine, which granted the corresponding certification. Patients voluntarily participated in this study after being informed in detail about the research project and signing the informed consent form, according to the declaration of Helsinki issued by the World Medical Association ( [@B35]).

Patients were diagnosed using established clinical, epidemiological, histopathological and parasitological criteria ([@B10]). LCL patients with one or two ulcerated lesions were not receiving treatment at the time of the study. ICL patients were identified by the prolonged natural history of their disease and the presence of single or multiple lesions with verrucous, sarcoidal or vegetative development and by the presence of plaques with numerous ulcers and an overall poor response to treatment. DCL patients presented with multiple lesions disseminated throughout the body, with one-40 years of parasitic evolution and several relapses after treatment with pentavalent antimonials. Parasitological confirmation of the clinical diagnosis was based on demonstration of *Leishmania* amastigotes in Giemsa or haematoxylin-eosin (H&E) staining of smears from biopsies.

Skin biopsies were obtained from all subjects after they signed the informed consent form. The specimens were embedded in Cryomatrix™ resin (Shandon Pittsburgh, USA), snap-frozen and stored in liquid nitrogen until examination. Frozen sections (5 μm) were cut at -30°C with a cryostat (Shandon, Pittsburgh, USA) and air-dried overnight prior to the immunostaining procedure.

*Antibodies* - All antibodies used were diluted in phosphate-buffered saline (PBS), pH 7.2. For chemokine characterisation of frozen sections, affinity-purified goat polyclonal antibodies directed to the following human chemokines were used: CXCL10 (IP-10) (sc-1406, Santa Cruz Biotechnology Inc, California, USA) (2 μg/mL), CCL8 (MCP2) (sc-1307, Santa Cruz Biotechnology Inc, California, USA) (2 μg/mL), CCL4 (MIP1β) (AF-271-NA, R&D Systems Inc, USA) (5 μg/mL) and CXCL8 (IL-8) (AF-208-NA, R&D Systems, Inc, USA) (2.5 μg/mL). For CCL11 (eotaxin) detection, a rat monoclonal antibody (MAB-320, R&D Systems Inc, USA) (5 μg/mL) was used. Mouse monoclonal antibodies against the following human chemokine receptors were purchased from R&D Systems Inc (Minneapolis, USA) (5 μg/mL): CXCR3 (MAB-160), CCR3 (MAB-155), CCR5 (MAB-181) and CCR7 (MAB-197). Biotinylated horse anti-mouse IgG, biotinylated horse anti-goat IgG or biotinylated rabbit anti-rat secondary antibodies were used at 15 μg/mL (all Vector Laboratories, Burlingame, USA). All antibodies were diluted in PBS.

*Immunohistochemistry* - For immunohistochemistry, we used a previously described immunostaining procedure ([@B11]). Briefly, the samples were hydrated in PBS and sequentially incubated for 60 min at room temperature with a primary mouse monoclonal antibody or for 120 min at 37°C with a goat polyclonal antibody. Then, the samples were incubated with a biotinylated horse anti-mouse IgG, a biotinylated horse anti-goat IgG or a biotinylated rabbit anti-rat IgG diluted 1:100 (15 μg/mL, all from Vector Laboratories, Burlingame, USA) for 30 min. Next, the samples were treated with the Vectastain ^®^ Elite ABC kit (Vector Laboratories, Burlingame, USA) for 30 min. Incubations were performed in a Shandon Coverplate™ system (Pittsburgh, USA) and 5-min washes with PBS were performed between steps. Reactions were developed for 3 min with Vector ^®^ NovaRed™ substrate. The sections were then washed, counterstained with Harris haematoxylin, dehydrated and mounted with DPX (BDH Chemicals Ltd, Pool, England). Omission of the primary antibody served as the control.

*Leukocyte quantification* - Cells were counted using a light microscope (Leica, Wetzlar, Germany) connected to a colour video monitor that was calibrated to determine the number of cells/mm ^2^ . Only cells with a visible nucleus and red immunostaining were counted as positive. To obtain a representative sample of the lesions, two non-serial alternate sections were immunostained and counted for each cell marker. All of the fields of interest were counted in each section at a magnification of 400X, resulting in 2-4x10 ^4^ counted cells per section. The percentage of each phenotype was calculated. Previous counts of the nucleated cells in H&E-stained sections indicated that there were approximately 6,000 cells/mm ^2^ in the infiltrate of LCL and ICL patients and approximately 4,000 cells/mm ^2^ in DCL patients.

*Statistical analysis* - The distribution of the data was analysed with the Kalmogorov-Smirnov normality test. Because not all variables from the leukocyte quantification had a normal distribution and the size of the patient groups was small, the comparison between groups was performed using the nonparametric Mann-Whitney *U* test. The data are represented as the numbers of positive cells/mm ^2^ (medians, range and interquartile range) and p values less than 0.05 were considered significant. Correlations between the variables were analysed using the Spearman rank coefficient. Moreover, clinical data depicting the leishmanin test values and the time of evolution showed a normal distribution and the comparison between groups was therefore performed using an unpaired t test. All tests were performed using GraphPad InStat 3.02 (GraphPad Software, San Diego, California USA) (graphpad.com).

RESULTS
=======

Three groups of patients with different clinical forms of cutaneous leishmaniasis were studied (LCL, n = 20; ICL, n = 5; DCL, n = 10). These patients were diagnosed using established clinical, epidemiological, histopathological and parasitological criteria ([@B10] ).

The clinical examination showed that LCL patients had one or two localised ulcers with infiltrated borders in exposed areas; the mean evolution period was 2.2 months at the time of the first medical consultation. ICL patients were identified according to the presence of single or multiple lesions with verrucous, sarcoidal or vegetative plaques with 6 ± 2.3 months of evolution and DCL patients presented with a prolonged natural history (118 ± 132 months) and multiple disseminated lesions such as papules, plaques and nodules. The leishmanin skin test was strongly positive in LCL (21.2 ± 8.3, mean ± standard deviation) and ICL patients (15.3 ± 4.8), whereas DCL patients were negative (0.7 ± 2.4) ([Table](#t01){ref-type="table"}). The histological analysis of skin biopsies confirmed the diagnosis of LCL, ICL or DCL, with the variable presence of *Leishmania* parasites in LCL and ICL patients and large numbers of parasites in DCL patients.

TABLEClinical characteristics of different groups of patientsDiagnosticAge(mean ± SD)Leishmanin(mm)(mean ± SD)Time of evolution(months)(mean ± SD)LCL (n = 20)34 ± 1621.2 ± 8.3 *^a^*2.2 ± 1.8 *^a^*ICL (n = 5)36 ± 2015.3 ± 4.8 *^a^*6 ± 2.3 *^a^*DCL (n = 10)17 ± 130.7 ± 2.4118 ± 132[^1]

The immunohistological analysis showed a tendency for a higher density of CXCL10-positive cells in the granulomas of patients with LCL (median 250 cells/mm ^2^ , ranging from 0-888 cells/mm ^2^ ) and ICL (263, 0-525 cells/mm ^2^ ) as compared to DCL patients (138, 0-488 cells/mm ^2^ ) ([Fig. 1A](#f01){ref-type="fig"}). All patients with LCL and ICL and 70% of those with DCL showed CXCL10 expression in the epidermis, sweat glands and nerve fibres ([Fig. 2A-C](#f02){ref-type="fig"}). The analysis of CCL4 and CCL8 expression showed similar results for infiltrating granuloma cells and an augmented density of CCL4- and CCL8-positive cells in patients with LCL (406, 0-1,050 CCL4+ cells/mm ^2^ and 487, 0-1,238 CCL8+ cells/mm ^2^ , respectively) as compared to DCL (75, 0-925 CCL4+ cells/mm ^2^ and 100, 0-825 CCL8+ cells/mm ^2^ ) (both p \< 0.05) ([Fig. 1A](#f01){ref-type="fig"}, C). Although no differences were observed regarding CCL11 expression in the infiltrate between groups, 35% of patients with LCL, 80% of those with ICL and 50% of those with DCL exhibited CCL11-positive DCs in the epidermis ([Fig. 2G](#f02){ref-type="fig"}). The density of CCL11-positive epidermal DCs was also higher in ICL (150, 0-225 cells/mm ^2^ ) and DCL (38, 0-138 cells/mm ^2^ ) patients than in LCL patients (0, 0-188 cells/mm ^2^ , p \< 0.05) ([Fig. 1C](#f01){ref-type="fig"}).

Fig. 1chemokines and chemokine receptors in lesions of different clinical forms of American cutaneous leishmaniasis. A, B: density of CXCL10, CCL4, CXCR3 and CCR5 positive cells; C, D: density of CCL11, CCL8 and CCR3 positive cells; E: density of CXCL8; F: CCR7 positive cells. Data are represented as medians and interquartile range patients with localised cutaneous leishmaniasis (LCL) (n = 20), intermediate cutaneous leishmaniasis (ICL) (n= 5) and diffuse cutaneous leishmaniasis (DCL) (n = 10). Asterisk means p \< 0.05 comparing LCL with DCL, LCL with ICL and LCL with ICL by the Mann-Witney *U* test.

Fig. 2immunolabelling of chemokine in lesions American cutaneous leishmaniasis. Detection of CXCL10 on the epidermal cells (A), nerve fibres (B) and glands (C) of a patient with localised cutaneous leishmaniasis (LCL) with their respective negative controls (D, E, F). Epidermal CCL11+ dendritic cells (D) in a patient with diffuse cutaneous leishmaniasis (DCL). Infiltrating CCR3+ cells (E) in a patient with DCL. CCR7+ cells in a patient with LCL (F). Respective negative controls (J-L). Original magnification: 400X and 200X (A, D).

Furthermore, when we evaluated the chemokine receptors expressed on the infiltrating cells in the lesion, we found higher numbers of CXCR3-positive cells in patients with LCL (1,637, ranging from 425-2,750 cells/mm ^2^ ) and ICL (1,722, 1,400-2,000 cells/mm ^2^ ) as compared to those with DCL (950, 125-1,313 cells/mm ^2^ , p \< 0.05) ([Fig. 1B](#f01){ref-type="fig"}), indicating a positive correlation with the expression of its ligand CXCL10 (r = 0.3984; p = 0.0239). Although these differences were not significant, we observed a tendency for an increased density of CCR5-positive cells in LCL patients (575, 0-1,763 cells/mm ^2^ ) compared to DCL patients (238, 0-1,163 cells/mm ^2^ ) ([Fig. 1B](#f01){ref-type="fig"}). However, no correlation between CCR5 and its ligand CCL4 was observed. Moreover, no significant differences were observed regarding the density of CCR3+ cells in the different clinical forms of leishmaniasis evaluated (LCL, 500, 0-1,765 cells/mm ^2^ ; ICL, 638, 0-1,025 cells/mm ^2^ ; DCL, 307, 0-11,253 cells/mm ^2^ ) ([Fig. 1D](#f01){ref-type="fig"}) and CCR3 expression was not correlated with that of its ligand CCL11.

In addition, we evaluated CXCL8 expression, which plays a role in the recruitment of PMN cells. The expression of this chemokine was not significantly different between the groups of patients evaluated ([Fig. 1E](#f01){ref-type="fig"}). However, we found clear differences in CCR7 expression in granuloma cells from patients with different clinical forms; lesions from patients with LCL showed a higher density of CCR7-positive cells (887, 288-1,763 cells/mm ^2^ ) as compared to patients with ICL (173, 0-775 cells/mm ^2^ , p \< 0.05) or DCL (536, 100-1,300 cells/mm ^2^ , p \< 0.05) ([Fig. 1F](#f01){ref-type="fig"}). In addition, 30% of patients with LCL and 20% of patients with ICL, but none of the DCL patients, showed CCR7-positive epidermal DCs ([Figs 1F](#f01){ref-type="fig"}, [2I](#f02){ref-type="fig"}).

DISCUSSION
==========

Chemokines play an important role during innate and adaptive immunity in cutaneous leishmaniasis. It is known that macrophages produce CCL4, an inflammatory chemokine that recruits CD4+ lymphocytes ([@B26]) and is increased in the serum of patients with cutaneous leishmaniasis ([@B34]). In lesions, we observed elevated levels of CCL4 and CCL8 in LCL patients and these chemokines contribute to the recruitment of macrophages and DCs activated by CCL2 in synergy with IFN-γ ([@B24], [@B15]). In contrast, the expression of CXCL8 was similar in LCL, ICL and DCL patients. It has been demonstrated that human monocytes infected with *Leishmania major* demonstrate chemotactic activity for neutrophils and monocytes due to CXCL8 production ([@B05]). Moreover, contact with *Leishmania* induces the release of CXCL8 by PMNs (van Zandbergen et al. 2002), which indicates a potential role for neutrophils in the pathogenesis of active forms of leishmaniasis, as previously demonstrated by [@B06] in mucosal leishmaniasis associated with a Th17 response.

Immature DCs are able to internalise parasites and migrate to the regional lymph node for antigen presentation. This migratory ability depends on the expression of CCR7, the receptor for CCL21 and CCL19 produced in secondary lymphoid tissues ([@B13]). These results suggest that patients with LCL have improved migration of DCs to lymph nodes. In addition, epidermal DCs may be activated to migrate in a CCR7-dependent manner in patients with LCL and ICL but not DCL and this may contribute to the development of a more efficient adaptive response against the parasite in LCL than in other active clinical forms of the disease. It has also been demonstrated that reduced expression of CCR7 and defective DC migration play a major role in the pathogenesis of visceral leishmaniasis in mice ([@B03], [@B02]). Furthermore, the expression level of CCR7 and the DC response to the CCR7 ligand CCL21 was shown to be increased after contact with *L. major* in both resistant and susceptible mice ([@B29]). Thus, it is possible that the modulation of chemokine receptor expression on DCs depends upon the infecting *Leishmania* species.

The chemokines produced at the site of infection are critical for determining the composition of the infiltrating cells. In the lesions of LCL and ICL patients, elevated levels of CXCL10 are produced by the epidermis and stromal cells in the dermis, which attracts CXCR3+ cells, including Th1 cells ([@B27]) and the majority of the infiltrating cells in LCL and ICL lesions ([@B10]). These data confirm our previous result indicating that a Th1 response occurs in LCL, whereas a mixed Th1/Th2 response occurs in patients with ICL ([@B11]). Our results also coincide with those obtained by [@B14], who concluded that CXCR3+ Th1 lymphocytes are important for the resolution of cutaneous lesions in leishmaniasis. Furthermore, LCL patients with a high density of CXCR3+ cells respond well to treatment and may resolve lesions spontaneously, whereas ICL patients develop more severe and persistent lesions following primary infection. Thus, it is possible that patients with ICL and other relapsed forms of leishmaniasis mount a specific type of immune response. In addition, recent evidence demonstrates the involvement of a Th17 response in the pathogenesis of cutaneous, mucosal and post-kala-azar dermal leishmaniasis ([@B04], Lopez Kostka et al. 2009, [@B06], [@B16]).

Following early natural killer cell stimulation by IFN-γ, resident cells release elevated levels of CXCL10. Subsequently, CXCR3+ Th1 cells are recruited and more IFN-γ is released and keratinocytes are stimulated to produce more CXCL10 and CCL2 ([@B01]). In LCL and ICL patients, this continuous feedback loop leads to the elimination of most parasites by activated macrophages. However, the exacerbated immune response in ICL lesions leads to extensive tissue damage and this exacerbated immune response is likely due to failures in the regulation of the T cell response. For example, [@B25] demonstrated that CD4+CD25+ cells from asymptomatic individuals had a higher capacity to suppress IFN-γ production by CD4+ effector T cells than those from patients with chronic cutaneous leishmaniasis.

An association between CCL11 and the Th2 response in allergic dermatitis has been demonstrated ([@B36] ), as well as the expression of its receptor CCR3 on a subset of Th2 cells ([@B27]). In the present study, no significant differences in CCL11 or CCR3 expression were observed between groups of patients and this result agrees with recent work showing a similar expression pattern for CCL11 in patients with LCL and disseminated leishmaniasis in Brazil ( [@B20]). However, we observed in LCL lesions that CXCL10+ cells were twice as abundant as CCL11+ cells, whereas DCL lesions expressed similar levels of both chemokines. Furthermore, CCL11 is expressed on epidermal DCs in ICL and DCL patients, suggesting a role for these cells in the recruitment of CCR3+ cells in these patients.

This study detected expression of the chemokines CCL11 and CXCL10 in epidermal cells, suggesting the participation of the epithelium in the immune response against *Leishmania* . In support of this notion, growing evidence has demonstrated that chemokines released from epidermal cells control inflammatory skin diseases. Keratinocytes secrete both Th1 and Th2-associated chemokines, although the former type is more abundantly produced than the latter. In fact, decreasing keratinocyte production of chemokines is one of the therapeutic approaches to treat cutaneous inflammatory disorders ([@B31]).

In conclusion, for a protective immune response against *Leishmania*, the recruitment of appropriate leukocyte subpopulations resulting from the expression of chemokines and chemokine recognition by the appropriate receptors is essential. Our data suggest that the immune response in the lesions of LCL patients is associated with a CXCL10-dominated pattern of chemokine expression, which serves to attract CXCR3+ Th1 cells and promote efficient DC migration to lymph nodes via CCR7 expression. In contrast, DCL patients show low expression levels of chemokines associated with a Th1 response and instead express CCL11 in epidermal DCs, which contributes to the recruitment of CCR3+ cells. In both of these immune processes, the epidermis plays an important role as the inducer of the immune response via chemokine production by keratinocytes and epidermal DCs, which can be activated and migrate to lymph nodes in LCL patients, but not in DCL patients.

To the patients who participated in this study.

[^1]: *a* : p ≤ 0.05 compared with diffuse cutaneous leishmaniasis (DCL); ICL: intermediate cutaneous leishmaniasis; LCL: localised cutaneous leishmaniasis; SD: standard deviation.
